Abbas Ali Sangouni1,2, Hamid Mirhosseini3,4, Mahdieh Hosseinzadeh5,6. 1. Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 2. Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 3. Research Center of Addiction and Behavioral Sciences, Shahid Sadoughi University of Medical sciences, Yazd, Iran. 4. Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 5. Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. hoseinzade.mahdie@gmail.com. 6. Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. hoseinzade.mahdie@gmail.com.
Abstract
BACKGROUND: Attention deficit/hyperactivity disorder (ADHD) is the most common chronic mental and behavioral disorder among children. Some studies showed the lower levels of vitamin D in patients with ADHD compared with the healthy people. Few clinical trials were conducted in this field. The present study will be performed to examine the effect of vitamin D supplementation in children with ADHD. METHODS: We will conduct a double-blind, randomized controlled clinical trial to investigate the effect of vitamin D supplementation on brain waves, behavioral performance, serum nitric oxide, malondialdehyde, and high-sensitivity C-reactive protein in 50 patients with ADHD. The intervention group will receive one capsule 50,000 IU vitamin D every week, for 8 weeks. The control group will receive one placebo capsule containing 1000 mg olive oil every week. Electroencephalography will be performed for 10 min using Brain Master Discovery from 19 scalp sites both before the first intervention and the 10 sessions of the therapy. The artifact-free periods of 1-min electroencephalography data will be analyzed for quantitative electroencephalography measures. DISCUSSION: For the first time, this clinical trial will evaluate the effect of vitamin D supplementation on brain waves, serum nitric oxide, malondialdehyde, and high-sensitivity C-reactive protein in patients with ADHD. The results of the present clinical trial will provide a better vision about the vitamin D efficacy in patients with ADHD. TRIAL REGISTRATION: Registered on 5 November 2020 at Iranian Registry of Clinical Trials with code number IRCT20200922048802N1 ( https://www.irct.ir/trial/51410 ).
BACKGROUND: Attention deficit/hyperactivity disorder (ADHD) is the most common chronic mental and behavioral disorder among children. Some studies showed the lower levels of vitamin D in patients with ADHD compared with the healthy people. Few clinical trials were conducted in this field. The present study will be performed to examine the effect of vitamin D supplementation in children with ADHD. METHODS: We will conduct a double-blind, randomized controlled clinical trial to investigate the effect of vitamin D supplementation on brain waves, behavioral performance, serum nitric oxide, malondialdehyde, and high-sensitivity C-reactive protein in 50 patients with ADHD. The intervention group will receive one capsule 50,000 IU vitamin D every week, for 8 weeks. The control group will receive one placebo capsule containing 1000 mg olive oil every week. Electroencephalography will be performed for 10 min using Brain Master Discovery from 19 scalp sites both before the first intervention and the 10 sessions of the therapy. The artifact-free periods of 1-min electroencephalography data will be analyzed for quantitative electroencephalography measures. DISCUSSION: For the first time, this clinical trial will evaluate the effect of vitamin D supplementation on brain waves, serum nitric oxide, malondialdehyde, and high-sensitivity C-reactive protein in patients with ADHD. The results of the present clinical trial will provide a better vision about the vitamin D efficacy in patients with ADHD. TRIAL REGISTRATION: Registered on 5 November 2020 at Iranian Registry of Clinical Trials with code number IRCT20200922048802N1 ( https://www.irct.ir/trial/51410 ).
Authors: Sevil Bilir Goksugur; Ali Evren Tufan; Murat Semiz; Cemalettin Gunes; Mervan Bekdas; Mehmet Tosun; Fatih Demircioglu Journal: Pediatr Int Date: 2014-06-17 Impact factor: 1.524
Authors: Mark L Wolraich; Joseph F Hagan; Carla Allan; Eugenia Chan; Dale Davison; Marian Earls; Steven W Evans; Susan K Flinn; Tanya Froehlich; Jennifer Frost; Joseph R Holbrook; Christoph Ulrich Lehmann; Herschel Robert Lessin; Kymika Okechukwu; Karen L Pierce; Jonathan D Winner; William Zurhellen Journal: Pediatrics Date: 2019-10 Impact factor: 7.124
Authors: Guilherme V Polanczyk; Erik G Willcutt; Giovanni A Salum; Christian Kieling; Luis A Rohde Journal: Int J Epidemiol Date: 2014-01-24 Impact factor: 7.196
Authors: Stephen V Faraone; Philip Asherson; Tobias Banaschewski; Joseph Biederman; Jan K Buitelaar; Josep Antoni Ramos-Quiroga; Luis Augusto Rohde; Edmund J S Sonuga-Barke; Rosemary Tannock; Barbara Franke Journal: Nat Rev Dis Primers Date: 2015-08-06 Impact factor: 52.329
Authors: Mahmut Bulut; Salih Selek; H Serdar Gergerlioglu; Haluk A Savas; H Ramazan Yilmaz; Murat Yuce; Giyasettin Ekici Journal: J Psychiatry Neurosci Date: 2007-11 Impact factor: 6.186
Authors: Deepa Anand; Gabriela D Colpo; Gregory Zeni; Cristian P Zeni; Antonio L Teixeira Journal: Front Psychiatry Date: 2017-11-09 Impact factor: 4.157